The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

This website is intended for healthcare professionals only

Slide banner

RAS-PI3K⍺ Inhibitor (BAY 3674171)

See how this compound is being investigated across Bayer’s oncology pipeline

Explore the tumor types, areas of research, and clinical trials associated with this investigational compound.

PIXA_BAY_3674171_sqrt

Compound Overview

Rat sarcoma (RAS) proteins are membrane-bound guanosine triphosphatases that can cause cancers by activating the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) signaling pathways.1

RAS-PI3K⍺ inhibitor (BAY 3674171)*† is a small molecule for the treatment of RAS-driven tumors.2 It inhibits phosphatidylinositol 3-kinase alpha (PI3Kα) oncogenic signaling by blocking the interaction between RAS and PI3Kα.2 It is currently being evaluated in a phase I clinical trial of patients with advanced solid tumors.3

*Previously known as VVD-159642.
†Managed by Vividion Therapeutics.

Tumor Types

Gastrointestinal cancer (colorectal, pancreatic)
Lung cancer
Solid tumors

Area of Research

RAS-PI3Kα signaling

Clinical Trial

Tumor Type(s)

Phase

Status

Description

NCT Number

Lung Cancer, Solid Tumors, Gastrointestinal Cancer (Colorectal, Pancreatic)

I

Now Enrolling

A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3Kα Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors

NCT06804824

Bayer’s Oncology Pipeline Brochure

Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.

Download BrochurePDF (1.45 MB)

The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.